Evidence map›Paper›PMID 32475834›Full record

ArticleAnnals of the rheumatic diseases2021

Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon

Maximilian F Konig, Milena Gianfrancesco, Jinoos Yazdany, Philip C Robinson

Open access · greenAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Maximilian F KonigDivision of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.ORCID 0000-0001-5045-5255
Milena GianfrancescoDivision of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Jinoos YazdanyDivision of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Philip C RobinsonFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.ORCID 0000-0002-3156-3418
University of California, San Francisco · USJohns Hopkins University · USThe University of Queensland · AU

Funding

Multidisciplinary Rheumatology Training ProgramT32AR048522 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, LIVIA A CASCIOLA-ROSEN · 2003 to 2026
$6.4M
NIAMS NIH HHS T32 AR048522
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentLupus Erythematosus, SystemicHumansHydroxychloroquineLong-Term CareHydroxychloroquineepidemiologyhydroxychloroquinelupus erythematosus, systemic

Identifiers

PMID32475834
PMCPMC7704575
OpenAlexW3032727872

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.